Non-Hodgkin Lymphoma | Specialty

FDA Grants Priority Review to Loncastuximab Tesirine for Relapsed/Refractory DLBCL

November 20th 2020

November 20, 2020 - The FDA has granted a priority review designation to a biologics license application for loncastuximab tesirine for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

COVID-19 Delays FDA Review of Liso-Cel for Relapsed/Refractory Large B-Cell Lymphoma

November 17th 2020

November 17, 2020 - The review of the biologics license application for the CAR T-cell product lisocabtagene maraleucel for the treatment of adult patients with relapsed/refractory large B-cell lymphoma following at least 2 previous therapies has been delayed.

Reddy Reviews Paradigm Shifts in CD30-Positive PTCL, Next Steps for Research

November 16th 2020

Nishitha M. Reddy, MD, MBBS, discusses the significance of the ECHELON-2 trial in peripheral T-cell lymphoma, the need for novel therapies for those with CD30-negative disease, and the excitement surrounding duvelisib in the relapsed/refractory setting.

The Future of CAR T-Cell Therapy in Diffuse Large B-Cell Lymphoma

November 6th 2020

Impact of COVID-19 on CAR T-Cell Therapy for R/R DLBCL

November 6th 2020

Real-World Data for CAR T-Cell Therapy for R/R DLBCL

November 6th 2020

CAR T-Cell Therapy Clinical Trials for R/R DLBCL

November 6th 2020

Mechanism of CAR T Cells in R/R Diffuse Large B-Cell Lymphoma

November 6th 2020

Overview of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

November 6th 2020

Choosing the Optimal Frontline Approach for Low-Grade Follicular Lymphoma

November 4th 2020

Frontline treatment decisions for patients with follicular lymphoma can be guided by a general framework; the choice of therapy is often based on several factors such as indications of therapy, bulk of disease, comorbidities, and toxicity.

Making Progress Against Relapsed/ Refractory DLBCL Without CAR T

November 3rd 2020

A panel of lymphoma experts discuss several novel agents for relapsed/ refractory diffuse large B-cell lymphoma, some of which have been recently approved.

Off-the-Shelf CAR T-Cell Product CTX110 Shows Early Activity in Relapsed/Refractory CD19+ B-Cell Malignancies

October 23rd 2020

The investigational wholly-owned allogeneic CAR T-cell therapy CTX110 demonstrated dose-dependent efficacy and responses in patients with relapsed/refractory CD19-positive B-cell malignancies.

Copanlisib/Rituximab Prolongs PFS in Relapsed Indolent Non-Hodgkin Lymphoma

October 15th 2020

Copanlisib in combination with rituximab prolonged progression-free survival in patients with non-Hodgkin lymphoma who relapsed following 1 or more previous lines of rituximab-based therapy.

Mogamulizumab Significantly Boosts Outcomes in CTCL With Blood Involvement

October 13th 2020

Higher levels of blood tumor involvement were linked with more favorable outcomes in patients who received treatment with mogamulizumab compared with vorinostat in patients with 2 types of cutaneous T-cell lymphoma.

Dr. Martin on the Need for Head-to-Head Comparisons of BTK Inhibitors in MCL

October 12th 2020

Peter Martin, MD, discusses the need for head-to-head comparison of BTK inhibitors in mantle cell lymphoma.

Expert Perspectives in the Evolving Treatment Landscape for Follicular Lymphoma

October 12th 2020

Experts provide their perspectives on the evolving treatment landscape for patients with follicular lymphoma.

Lancet Oncology Data Reinforce Regulatory Approvals of Tazemetostat in Sarcoma, Follicular Lymphoma

October 9th 2020

Tazemetostat demonstrated durable responses and sustained safety in patients with epithelioid sarcoma and relapsed/refractory follicular lymphoma.

Current and Emerging Treatments in Follicular Lymphoma

October 9th 2020

Although the majority of patients with follicular lymphoma have a life expectancy similar to that of the general population, predicting which patients will relapse and finding therapies that provide durable responses in the relapsed or refractory setting remains an ongoing challenge.

Sequencing Challenges Arise Amid New Approvals in DLBCL Paradigm

October 5th 2020

Andrew M. Evens, DO, MSc, discusses the approval of 3 new regimens and how they have reformed the treatment paradigm of relapsed/refractory diffuse-large B-cell lymphoma.

Selinexor May Offer Post–CAR T Potential in Relapsed/Refractory DLBCL

September 30th 2020

Kami Maddocks, MD, discusses the significance of the selinexor approval in the diffuse large B-cell lymphoma treatment paradigm, emerging strategies that seek to address unmet needs, and remaining sequencing questions.